Impairments and Other Charges	3 Months Ended
Mar. 31, 2026
Restructuring and Related Activities [Abstract]
Impairments and Other Charges	Impairments and Other ChargesDuring the three months ended March 31, 2026, there were no amounts recorded in impairments and other charges. During the three months ended March 31, 2025, we recorded a pre-tax charge of $356 million primarily related to $107 million in severance expense as we rationalized global headcount to align with activity levels and $104 million of additional impairment associated with a strategic decision to market for sale a portion of our chemical business. Additionally, we recognized a $53 million impairment related to facility closures and lease terminations. Other charges of $92 million were primarily related to legacy environmental remediation cost estimate increases.

Impairments and Other Charges

3 Months Ended

Mar. 31, 2026

Impairments and Other ChargesDuring the three months ended March 31, 2026, there were no amounts recorded in impairments and other charges.

During the three months ended March 31, 2025, we recorded a pre-tax charge of $356 million primarily related to

$107 million in severance expense as we rationalized global headcount to align with activity levels and $104 million of

additional impairment associated with a strategic decision to market for sale a portion of our chemical business. Additionally,

we recognized a $53 million impairment related to facility closures and lease terminations. Other charges of $92 million were

primarily related to legacy environmental remediation cost estimate increases.